Ingredient or product comparison
GHK-Cu vs Minoxidil vs Finasteride: Head-to-Head
Mechanism Wnt activation, TGF-beta1 suppression, VEGF, DPC survival Potassium channel opening, vasodilation, VEGF 5-alpha reductase inhibition, reduces scalp DHT ~60% FDA-approved for hair Yes (topical) Yes (oral) Topical, injectable, microneedling Topical or
This source-based comparison does not add ratings or recommend a winner.
- Mechanism
- Wnt activation, TGF-beta1 suppression, VEGF, DPC survival
- Potassium channel opening, vasodilation, VEGF
- 5-alpha reductase inhibition, reduces scalp DHT ~60%
- FDA-approved for hair
- Yes (topical)
- Yes (oral)
- Topical, injectable, microneedling
- Topical or oral
- Oral
- Time to results
- 12 to 16 weeks (topical), 8 to 12 weeks (injectable)
- 12 to 24 weeks
- Standalone efficacy
- 7% hair count increase (topical); 26.5% regrowth (microneedling combo)
- 10 to 15% regrowth (meta-analysis average)
- 30 to 40% reduction in progression
- Alopecia types
- Androgenetic, diffuse thinning, post-inflammatory
- Androgenetic primarily
- Androgenetic only (male)
- OTC availability
- Yes (topical serums)
- Prescription only
- Finasteride remains the strongest standalone treatment for male androgenetic alopecia because it targets the root cause: DHT. No amount of GHK-Cu replicates a 60% reduction in scalp DHT.
- Minoxidil and GHK-Cu share VEGF upregulation but through different pathways (minoxidil via potassium channel/PHD inhibition, GHK-Cu via fibroblast stimulation). Using both provides additive angiogenic signaling. The Kuceki et al. study combined copper peptides with minoxidil for this reason (Kuceki et al., 2025).
- GHK-Cu fills gaps that neither drug addresses: TGF-beta1 suppression, Wnt pathway support, collagen cross-linking for follicle structural integrity, and DPC anti-apoptosis. Its side effect profile is milder than both alternatives. The evidence supports GHK-Cu as a complement to finasteride or minoxidil, targeting pathways they miss (Pickart & Margolina, 2018).